173 related articles for article (PubMed ID: 34550957)
1. Azstarys (serdexmethylphenidate/dexmethylphenidate) for ADHD.
Med Lett Drugs Ther; 2021 Oct; 63(1634):157-159. PubMed ID: 34550957
[No Abstract] [Full Text] [Related]
2. Jornay PM -- evening-dosed methylphenidate for ADHD.
Med Lett Drugs Ther; 2019 Aug; 61(1578):126-128. PubMed ID: 31386648
[No Abstract] [Full Text] [Related]
3. Drugs for ADHD.
Med Lett Drugs Ther; 2020 Jan; 62(1590):9-15. PubMed ID: 31999670
[No Abstract] [Full Text] [Related]
4. Transdermal methylphenidate (Daytrana) for ADHD.
Med Lett Drugs Ther; 2006 Jun; 48(1237):49-51. PubMed ID: 16785850
[No Abstract] [Full Text] [Related]
5. Quillivant XR--an extended release oral suspension of methylphenidate.
Med Lett Drugs Ther; 2013 Feb; 55(1409):10-1. PubMed ID: 23381227
[No Abstract] [Full Text] [Related]
6. Dexmethylphenidate extended release: a review of its use in the treatment of attention-deficit hyperactivity disorder.
Moen MD; Keam SJ
CNS Drugs; 2009 Dec; 23(12):1057-83. PubMed ID: 19958043
[TBL] [Abstract][Full Text] [Related]
7. An update on central nervous system stimulant formulations in children and adolescents with attention-deficit/hyperactivity disorder.
Chavez B; Sopko MA; Ehret MJ; Paulino RE; Goldberg KR; Angstadt K; Bogart GT
Ann Pharmacother; 2009 Jun; 43(6):1084-95. PubMed ID: 19470858
[TBL] [Abstract][Full Text] [Related]
8. Dexmethylphenidate (Focalin) for ADHD.
Med Lett Drugs Ther; 2002 May; 44(1130):45-6. PubMed ID: 12011757
[No Abstract] [Full Text] [Related]
9. Focalin XR for ADHD.
Med Lett Drugs Ther; 2009 Mar; 51(1308):22-4. PubMed ID: 19305368
[No Abstract] [Full Text] [Related]
10. Dexmethylphenidate extended release: in attention-deficit hyperactivity disorder.
Robinson DM; Keating GM
Drugs; 2006; 66(5):661-8; discussion 669-70. PubMed ID: 16620143
[TBL] [Abstract][Full Text] [Related]
11. [Efficacy and safety of stimulants and non-stimulants in adults with attention deficit hyperactivity disorder (ADHD)].
Golubchik P; Sever J; Weizman A
Harefuah; 2011 Oct; 150(10):788-90, 814. PubMed ID: 22111124
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of Ritalin LA, a new, once daily, extended-release dosage form of methylphenidate, in children with attention deficit hyperactivity disorder.
Biederman J; Quinn D; Weiss M; Markabi S; Weidenman M; Edson K; Karlsson G; Pohlmann H; Wigal S
Paediatr Drugs; 2003; 5(12):833-41. PubMed ID: 14658924
[TBL] [Abstract][Full Text] [Related]
13. Methylphenidate and dexmethylphenidate formulations for children with attention-deficit/hyperactivity disorder.
Sugrue D; Bogner R; Ehret MJ
Am J Health Syst Pharm; 2014 Jul; 71(14):1163-70. PubMed ID: 24973373
[TBL] [Abstract][Full Text] [Related]
14. The use of a laboratory school protocol to evaluate concepts about efficacy and side effects of new formulations of stimulant medications.
Swanson JM; Lerner M; Wigal T; Steinhoff K; Greenhill L; Posner K; Freid J; Wigal S
J Atten Disord; 2002; 6 Suppl 1():S73-88. PubMed ID: 12685522
[TBL] [Abstract][Full Text] [Related]
15. Methylphenidate transdermal system.
Mays DA; Findling R
J Am Acad Child Adolesc Psychiatry; 2005 Dec; 44(12):1223. PubMed ID: 16292112
[No Abstract] [Full Text] [Related]
16. A double-blind, randomized, placebo/active controlled crossover evaluation of the efficacy and safety of Ritalin ® LA in children with attention-deficit/hyperactivity disorder in a laboratory classroom setting.
Schulz E; Fleischhaker C; Hennighausen K; Heiser P; Oehler KU; Linder M; Haessler F; Huss M; Warnke A; Schmidt M; Schulte-Markworth M; Sieder C; Klatt J; Tracik F
J Child Adolesc Psychopharmacol; 2010 Oct; 20(5):377-85. PubMed ID: 20973708
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study.
Adler LA; Zimmerman B; Starr HL; Silber S; Palumbo J; Orman C; Spencer T
J Clin Psychopharmacol; 2009 Jun; 29(3):239-47. PubMed ID: 19440077
[TBL] [Abstract][Full Text] [Related]
18. A double-blind, placebo-controlled trial of dexmethylphenidate hydrochloride and d,l-threo-methylphenidate hydrochloride in children with attention-deficit/hyperactivity disorder.
Wigal S; Swanson JM; Feifel D; Sangal RB; Elia J; Casat CD; Zeldis JB; Conners CK
J Am Acad Child Adolesc Psychiatry; 2004 Nov; 43(11):1406-14. PubMed ID: 15502600
[TBL] [Abstract][Full Text] [Related]
19. Efficacy, Safety, and Tolerability of a Novel Methylphenidate Extended-Release Oral Suspension (MEROS) in ADHD.
Robb AS; Findling RL; Childress AC; Berry SA; Belden HW; Wigal SB
J Atten Disord; 2017 Dec; 21(14):1180-1191. PubMed ID: 24874348
[TBL] [Abstract][Full Text] [Related]
20. Dexmethylphenidate--Novartis/Celgene. Focalin, D-MPH, D-methylphenidate hydrochloride, D-methylphenidate, dexmethylphenidate, dexmethylphenidate hydrochloride.
Drugs R D; 2002; 3(4):279-82. PubMed ID: 12455205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]